Income Statement

v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Condensed Consolidated Statements Of Operations        
Revenues, net $ 98,674 $ 210,544 $ 246,398 $ 344,771
Operating expenses:        
Cost of implants and other costs 52,993 166,665 85,798 190,015
Research and development 43,339 59,006 51,570
Selling, general and administrative 785,834 778,693 1,377,256 1,285,293
Depreciation and amortization 1,302 8,465 4,748 16,854
Total operating expenses 840,129 997,162 1,526,808 1,543,732
Loss from operations (741,455) (786,618) (1,280,410) (1,198,961)
Other income (expenses):        
Interest expense, net (480,132) (459,064) (942,923) (10,220,569)
Gain on settlement of debt 285,924 285,924
Gain (loss) on change in fair value of derivative liability 12,263,680 (15,897,993)
Total other income (expenses) (480,131) 12,090,540 (942,923) (25,832,638)
Net (loss) income before provision for income taxes (1,221,587) 11,303,922 (2,223,333) (27,031,599)
Income taxes
Net (loss) income (1,221,587) 11,303,922 (2,223,333) (27,031,599)
Non-controlling interest 45 45
NET (LOSS) INCOME ATTRIBUTIBLE TO BIOCORRX, INC. $ (1,221,542) $ 11,303,922 $ (2,223,288) $ (27,031,599)
Net (loss) income per common share, basic $ (0.00) $ 0.05 $ (0.01) $ (0.12)
Net (loss) income per common share, diluted $ 0.00 $ 0.02 $ (0.01) $ (0.12)
Weighted average number of common shares outstanding, basic 250,493,153 241,730,516 248,407,279 222,279,257
Weighted average number of common shares outstanding, diluted 250,493,153 579,668,702 248,407,279 222,279,257

Source